互白素1β调解了过敏性鼻炎中鼻膜上皮质屏障功能障碍的发病过程
Hanrui Wang1,2,3,4, Xiaoyu Song1,2,3,4, Yao Wang1,2,3,4
1Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, People's Republic of China.
Journal of inflammation research
|November 26, 2024
概括
干白素-1β (IL-1β) 在过敏性鼻炎 (AR) 中损害鼻壁. 抑制IL-1β或其受体可以保护鼻膜屏障,这表明IL-1β是潜在的AR治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 皮质生物学 皮质生物学
背景情况:
- 鼻膜上皮屏障是过敏性鼻炎 (AR) 的核心.
- 干白素-1β (IL-1β) 参与免疫炎症,并影响各种上皮屏障.
- 在AR鼻中IL-1β的特定作用仍未得到研究.
研究的目的:
- 为了研究IL-1β对AR鼻膜上皮质屏障的影响.
- 阐明IL-1β在AR中的作用的基本机制.
- 评估在AR中准IL-1β的治疗潜力.
主要方法:
- 通过使用Dermatophagoides pteronyssinus 1.诱导AR小鼠模型.
- 人类鼻粘膜上皮细胞 (HNEpCs) 被过敏原刺激.
- 分析了IL-1β,CLDN1和OCLN的表达.
- 外源IL-1β和受体 (IL-1R1) 抑制被用来探索机制.
主要成果:
- 对过敏原的暴露增加了IL-1β的表达,并在小鼠鼻腔粘膜和HNEpC中减少了屏障蛋白 (CLDN1,OCLN).
- 在HNEpCs中,IL-1β直接降低了上皮屏障蛋白的表达.
- 抑制IL-1β或IL-1R1缓解了上皮质屏障损伤.
结论:
- 在AR中,IL-1β对鼻膜上皮屏障产生有害影响.
- 准IL-1β或其受体IL-1R1为鼻腔屏障提供了一种保护策略.
- IL-1β代表了AR治疗的有前途的治疗标.
相关概念视频
T Cell Types and Functions
954
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
954
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
352
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
352
Asthma: Pathogenesis and Management
351
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
351
Allergic Reactions
27.2K
Overview
27.2K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K


